This research study is currently not recruiting patients.

Achillion ACH471-201

Brief description of study

A randomized, placebo-controlled, double-blinded (sponsor-open) study with six months of dosing. The study will include approximately 20 patients with C3 glomerulopathy who have not undergone renal transplant. Patients will be randomized 1:1 to ACH-0144471 or placebo. The randomization will be stratified by the disease diagnosis: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).


Clinical Study Identifier: s16-02046
ClinicalTrials.gov Identifier: NCT03369236